Jump to main content
Jump to site search


Discovery of napabucasin derivatives for the treatment of tuberculosis

Author affiliations

Abstract

Tuberculosis is the contagious disease responsible for the highest number of deaths worldwide. Here, we screened a commercially available compound library and found napabucasin to possess a moderate anti-tubercular activity against M. tuberculosis H37Ra (MIC 2.5 μg mL−1, 10.4 μM). Three series of napabucasin derivatives were further evaluated for their in vitro anti-tubercular activities against Mtb H37Ra. The activity of most derivatives was either retained or enhanced compared with that of napabucasin. Compound 3s was the most active compound showing a MIC value of 0.3125 μg mL−1 (0.9 μM). Furthermore, several compounds were selected and evaluated against the Mtb H37Rv standard strain and six Mtb clinical isolates. Importantly, these compounds were found to be effective against Mtb clinical isolates with multi-resistance to isoniazid, rifampicin, and ethambutol.

Graphical abstract: Discovery of napabucasin derivatives for the treatment of tuberculosis

Back to tab navigation

Supplementary files

Publication details

The article was received on 27 May 2019, accepted on 10 Jul 2019 and first published on 16 Jul 2019


Article type: Research Article
DOI: 10.1039/C9MD00295B
Med. Chem. Commun., 2019, Advance Article

  •   Request permissions

    Discovery of napabucasin derivatives for the treatment of tuberculosis

    C. Li, Y. Tang, Z. Sang, Y. Yang, Y. Gao, T. Yang, C. Fang, T. Zhang and Y. Luo, Med. Chem. Commun., 2019, Advance Article , DOI: 10.1039/C9MD00295B

Search articles by author

Spotlight

Advertisements